Identification of hub genes associated with RNAi-induced silencing of XIAP through targeted proteomics approach in MCF7 cells

Mehdi Agha Gholizadeh, Fatemeh T. Shamsabadi, Ahad Yamchi, Masoud Golalipour, Gagan Deep Jhingan and Majid Shahbazi

Abstract

Background: The X-linked inhibitor of apoptosis protein (XIAP) is the most potent caspase inhibitor of the IAP family in apoptosis pathway. This study aims to identify the molecular targets of XIAP in human breast cancer cells exposed to XIAP siRNA by proteomics screening. The expression of XIAP was reduced in MCF-7 breast cancer cells by siRNA. Cell viability and the mRNA expression level of this gene were evaluated by MTS and quantitative real-time PCR procedures, respectively. Subsequently, the XIAP protein level was visualized by Western blotting and analyzed by two-dimensional (2D) electrophoresis and LC–ESI–MS/MS.

Results: Following XIAP silencing, cell proliferation was reduced in XIAP siRNA transfected cells. The mRNA transcription and protein expression of XIAP were decreased in cells exposed to XIAP siRNA than si-NEG. We identified 30 proteins that were regulated by XIAP, of which 27 down-regulated and 3 up-regulated. The most down-regulated proteins belonged to the Heat Shock Proteins family. They participate in cancer related processes including apoptosis and MAPK signaling pathway. Reduced expression of HSP90B1 was associated with apoptosis induction by androgen receptor and prostate specific antigen. Suppression of XIAP resulted in the enhancement of GDIB, ENO1, and CH60 proteins expression. The network analysis of XIAP-regulated proteins identified HSPA8, HSP90AA1, ENO1, and HSPA9 as key nodes in terms of degree and betweenness centrality methods.

Conclusions: These results suggested that XIAP may have a number of biological functions in a diverse set of non-apoptotic signaling pathways and may provide an insight into the biomedical significance of XIAP over-expression in MCF-7 cells.

Keywords: Breast cancer, XIAP, RNA interference, Apoptosis, Molecular targets, Proteomics

Background

Inhibition of the apoptotic signaling pathway plays an important role in the initiation and progression of human cancers [1]. Various molecular mechanisms cause inhibition of apoptosis in cancer cells. High expression level of inhibitor apoptosis proteins (IAPs) is one of the important mechanisms that prevent apoptosis. IAPs are a family of anti-apoptotic proteins that are conserved throughout evolution from drosophila to vertebrates [2]. These proteins directly inhibit the terminal effector caspases through BIR-dependent recognition [3]. Over-expression of the IAPs occurs in many human tumor types that lead to cancer cell survival [4, 5]. In human,
eight members of the IAP family have been identified. The most potent caspase inhibitor of this family is X-linked inhibitor of apoptosis (XIAP) [6]. XIAP inhibits the enzymatic activity of caspases at both the initiation phase and the execution phase by binding to caspases of 9, 3, and 7 [7]. High levels of XIAP were detected in human tumors and has been shown to confer the resistance to the chemotherapy drugs [8, 9]. Also, high throughput data analysis revealed that the expression of this gene remarkably increased in most of the cancers except ovary, kidney renal clear cells, and uterine cancers [10]. A logical strategy, therefore, to overcome the resistance to apoptosis is to target the factors that inhibit apoptosis pathway.

Our recent trends in the identification of regulated proteins by the critical genes in breast cancer cell progression such as PTTG1 and FOXO [11, 12], resulted in a proliferation of studies that have led to a renewed interest in XIAP. Accordingly, this study was designed to investigate the XIAP-regulated proteins by its suppression in MCF-7 cells. Specific down-regulation of XIAP by siRNA inhibited the growth of MCF-7 cells in vitro. We have also undertaken a proteomics pattern and pathway analysis to identify the biological targets of XIAP protein. XIAP suppression displayed enhanced expression of GDIB and CH60 along with metabolic gene encoding ENO1. The finding of this research revealed that XIAP may have a number of other biological functions in addition to participating in the mechanism of apoptosis, suggesting its potential value in tumor gene therapy.

Materials and methods

Materials

The human MCF-7 cells (breast carcinoma cell line) were obtained from Pasteur Institute of Iran (Tehran, Iran). Antibodies to XIAP; β-actin and the protease inhibitor cocktail were obtained from Sigma Co. (St. Louis, Mo). The XIAP siRNA was purchased from Santa Cruz Biotechnology, USA, and β-actin (Monoclonal Antibodies to XIAP; β-actin and the protease inhibitor cocktail were obtained from Pasteur Institute of Iran (Tehran, Iran). Antibodies to XIAP; β-actin and the protease inhibitor cocktail were obtained from Sigma Co. (St. Louis, Mo). The XIAP siRNA was purchased from Santa Cruz Biotechnology, Inc (sc-37508, Santa Cruz, Inc).

Cell culture and transfection

The breast cancer cell line MCF-7 were cultured at 37 °C in 5% CO2 in RPMI-1640 medium (Invitrogen; Carlsbad, CA) containing 10% FBS (GIBCO) and 1% penicillin/streptomycin (Sigma, St. Louis, Mo). The cells were seeded in 6-well plates in 2 ml antibiotic-free normal growth medium supplemented with FBS (2 × 10^5 cells/well). After incubation at 37 °C in 5% CO2 humidified atmosphere for 18 h, cells were transfected with 20 pmols XIAP siRNA through lipofection as described by the manufacturer. Then cells were incubated for 24, 48 and 72 h. Scrambled random siRNA (si-NEG) (Santa Cruz Biotechnology, Inc) was used as a control.

Real-time PCR

Total RNA was extracted using TRIZOL reagent (Invitrogen, Italy) according to the manufacturer’s instructions. Samples were treated with RQ1 RNase-Free DNase (Promega Corporation, USA) to eliminate possible contamination with genomic DNA. Strand cDNA synthesis performed with 1 µg DNase-treated RNA using the Transcriptor First Strand cDNA Synthesis Kit according to manufacturer’s instructions (Roche Applied Science). Real-time RT-PCR assay was performed on XIAP, ENO1, CH60, CRK, SAM50 and GAPDH genes using ABI 7300 real-time PCR systems (Applied Biosystems, Foster City, CA) thermal cycler detection system. The threshold cycle (Ct) of technical triplicates data were measured for each cDNA in the real-time PCR analysis. Each reaction consisting of 12.5 µl SYBR ® Green PCR Master Mix (Applied Biosystems, Foster City, CA), 1 µl cDNA (50 ng), 0.5 µl of each primer (10 pmol) and 10.5 µl nuclease-free water to conduct PCR in a 25 µl of a reaction mixture. The characteristics of primers were indicated in Table 1. We used the REST (Relative Expression Software Tool) software to analyze the reactive changes in gene expression. The number of specific transcripts was normalized to the expression level of GAPDH as the housekeeping gene.

Western blotting

Total protein was isolated by lysis buffer (contain 5% SDS, Triton X100, 100 mM Tris–HCl (PH = 4.7), sodium deoxycholate 150 mM NaCl, 5 mM EDTA, 10% glycerol) and 1% protease inhibitor Cocktail (Sigma-Aldrich). The protein concentration was quantified using Bradford assay. Protein levels were visualized by immunoblotting using antibodies against human XIAP (sc-11426, Santa Cruz Biotechnology, USA), and β-actin (Monoclonal Antibodies to XIAP; β-actin and the protease inhibitor cocktail were obtained from Pasteur Institute of Iran (Tehran, Iran). Antibodies to XIAP; β-actin and the protease inhibitor cocktail were obtained from Sigma Co. (St. Louis, Mo). The XIAP siRNA was purchased from Santa Cruz Biotechnology, Inc (sc-37508, Santa Cruz, Inc).

| Gene | Primer sequence (5’ to 3’) | Amplicon size |
|------|---------------------------|---------------|
| XIAP | F ACCGTGGTCCGTCTTTAGTT | 133           |
|      | R TGGCTGGACACTTATTTTCAAGATA |               |
| ENO1 | F CCTGCCTGTTAGCAAGAA | 108           |
|      | R GGCGTGGGACAAAACACTTG |               |
| CH60 | F GACGACCTGTCGCG | 78            |
|      | R ATCTGGCGAAGACTGTTGGG |               |
| CRK  | F AATCCGGGACAGCCTGAAG | 142           |
|      | R ACCCTCTGTTTACCTCCAA |               |
| SAM50| F ATGGAAGACCAGCCACACTG | 128           |
|      | R TGCCGGTGGAAGAGATGAT |               |
| GAPDH | F GTGTGGTCCCTCCTGACTTCAACA | 121           |
|      | R GTGTAAGCACCATTGTGGT |               |

“F” and “R” are abbreviation of Forward and Reverse primers.
Anti-β-actin, Sigma-Aldrich). Briefly, equivalent amounts of protein were resolved by SDS/polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. For blocking, membrane incubated with 1X PBS, 0.1% Tween-20, 5% non-fat dry milk powder at 4 °C for 75 min. After washing, membrane incubated with anti-XIAP (1:800 dilution) and anti-β-actin (1:500 dilution) antibodies at 4 °C overnight. Subsequent washing the membrane with PBS for 5 times (1, 5, 10, 15, and 20 min), the membrane was incubated with the secondary antibody (goat Anti-Mouse IgG horseradish peroxidase-conjugated, Santa Cruz Biotechnology, USA) at a dilution of 1:500 for 2 h at room temperature. Protein bands were developed by Chemiluminescence using the Amersham ECL Detection Kit (ECL, ab65623, Abcam). Band densities were determined using NIH ImageJ software (US National Institutes of Health, Bethesda, MA, USA).

2D electrophoresis and image analysis
Total protein was quantified by 2-DE quant kit (GE Healthcare) assay using BSA as standard. First dimension electrophoresis was performed with IPG strips (18 cm 3–10 NL, Immobiline Dry Strip; Bio-Rad) in IPGphor system (GE Healthcare) as previously described [13]. In brief, the rehydrated strips with 300 μL of loading buffer containing 1 mg of the protein sample were applied for the isoelectric focusing at 300 V for 2 h, 500 V for 2 h and 1000 V for 2 h. Then voltage ramped up to 8000 V in 5 h and continued at this voltage for a further 60,000 V. Focused strips were equilibrated for 15 min in reducing equilibration buffer (6 M urea, 50 mM Tris–HCl, pH 8.8, 30% v/v glycerol, 2% w/v SDS, a trace of bromo phenol blue and 1% w/v DTT) and for another 15 min in alkylating equilibration buffer with 2.5% w/v iodoacetamide instead of 1% DTT. The strips were transferred onto 12.5% SDS-PAGE gels and second dimension electrophoresis was performed at a constant current of 7.5 mA per gel for 30 min and 20 mA per gel for 5 h at 20 °C. Gels were fixed for 1 h in 40% methanol 10% acetic acid, washed for 30 min in ultrapure water and then stained with colloidal Coomassie Brilliant Blue G-250 [6]. Stained gels were scanned with Scanner Perfection (GE Healthcare) and image analysis, spot detection and spot pairing carried out using Image Master 2D Platinum 6.0 (GE Healthcare). Scatter plots between gels were used to estimate gel similarity (Image Master 2D Platinum 6.0 user manual). For selected protein spots, the corresponding relative spot intensity of three different experiments was measured. The induction ratios of each selected protein spot were determined by comparing in-gel intensities of XIAP siRNA and si-NEG transfected. These proteins-coding genes were introduced as the differentially expressed genes (DEGs).

Protein identification by LC–ESI–MS/MS
The spots of protein were manually excised from the gels and completely destained with a 1:1 (v/v) solution of acetonitrile and 25 mM ammonium bicarbonate. The destained pieces were equilibrated in 5 mM ammonium bicarbonate, dried by vacuum centrifugation and finally digested in 5 mM ammonium bicarbonate supplemented by trypsin (10 ng/μl, sequencing grade modified trypsin, Promega) for at least 16 h at 37 °C. Digestion was stopped by addition of 1 μl of 10% trifluoroacetic acid (TFA) and supernatants collected. Gel pieces were extracted with 50 μl of a 1:1 (v/v) solution of acetonitrile and 0.1% TFA. Supernatants collected from the same samples pooled and dried by vacuum centrifugation. Samples were dissolved in 10 μl of 2% acetonitrile, 0.1% TFA. All the analysis was performed using a Q-TRAP (LC packings and Applied Biosystems/MDS Sciex) LC–MS/MS system as described by Boudart et al. [7]. Mass data collected during analysis was processed by the Analyst software (Applied Biosystems/MDS Sciex) and the MS/MS lists used to search the Swiss-Prot database. Data lists blasted against the databases using the Mascot software (2.2.3). The search strategy was carried out according to some inclusion criteria including up to two missed cleavages, 0.5 Mass accuracy (for parent and the fragment ions), and variable modifications set for deamidation of arginine or glutamine and oxidation of methionine. Probability-based MASCOT scores used to evaluate the protein identifications. We used the MFPaQ program [14] version 4 to validate the data.

Cell proliferation assay
Cell viability was determined by MTS dye-reduction assay according to the provided instruction (Promega). The cells were seeded at a density of 2 × 10^3 cells/well in 96-well plates cultured in media containing 100 μl of normal growth medium supplemented with 5% FBS. Subsequently, the viability of cells was evaluated by MTS reagent at 0, 24 and 48 h after transfection. Absorbance was determined by the BioTek Plate Reader at 490 nm. All assays were performed in triplicate and three times.

System biology analysis of the regulated proteins by XIAP
In order to identify the regulated proteins by XIAP in breast cancer cells, the classification of differentially expressed proteins (DEPs) was performed by some bioinformatics databases. The STRING (v 11.0) database was applied for the interaction of XIAP with other DEPs. The included criteria for the selection of the partner of these proteins was the confidence with at least medium (score...
0.4) and Kmeans clustering constructed according to the experimental, textmining, co-expression, and database knowledge. Moreover, gene ontology (GO) enrichment analysis and significant pathways were assessed by PANTHER (v 14.0) and KEGG resources, respectively.

In order to identify the hub genes in the protein–protein interaction network, network analyzer tool in Cytoscape software was applied. Then, the protein interaction relationship network was visualized based on the degree parameter.

Statistical analysis
Statistical analysis was carried out using the SPSS version 18.0 software (SPSS Inc., Chicago, IL). Data were presented as mean value ± SD. Statistical analysis of the data was performed by the Student t test or the Mann–Whitney U test with the SigmaStat 3.0 software (SPSS). For all tests, a P-value ≤ 0.05 was considered as statistically significant.

Results
Declining XIAP mRNA and protein expression by XIAP siRNA
The XIAP mRNA was found to be successfully down-regulated at 24, 48 and 72 h post-transfection (Fig. 1a). As can be seen from this Figure, the expression of XIAP was significantly reduced at all times, especially at 24 and 48 h (P < 0.0001).

The protein expression of XIAP in response to the siRNA against XIAP in MCF-7 cells was reduced at 24, 48 and 72 h (Fig. 1b). To semi-quantify the amount of XIAP protein and evaluate the efficient acting time of siRNA against XIAP in MCF-7 cells was reduced at 24, 48 and 72 h (Fig. 1b). To semi-quantify the amount of XIAP protein and evaluate the efficient acting time of siRNA against XIAP in MCF-7 cells was reduced at 24, 48 and 72 h (Fig. 1b). To semi-quantify the amount of XIAP protein and evaluate the efficient acting time of siRNA against XIAP in MCF-7 cells was reduced at 24, 48 and 72 h (Fig. 1b). To semi-quantify the amount of XIAP protein and evaluate the efficient acting time of siRNA against XIAP in MCF-7 cells was reduced at 24, 48 and 72 h (Fig. 1b). To semi-quantify the amount of XIAP protein and evaluate the efficient acting time of siRNA against XIAP in MCF-7 cells was reduced at 24, 48 and 72 h (Fig. 1b). To semi-quantify the amount of XIAP protein and evaluate the efficient acting time of siRNA against XIAP in MCF-7 cells was reduced at 24, 48 and 72 h (Fig. 1b). To semi-quantify the amount of XIAP protein and evaluate the efficient acting time of siRNA against XIAP in MCF-7 cells was reduced at 24, 48 and 72 h (Fig. 1b). To semi-quantify the amount of XIAP protein and evaluate the efficient acting time of siRNA against XIAP in MCF-7 cells was reduced at 24, 48 and 72 h (Fig. 1b).

XIAP siRNA inhibits the MCF-7 proliferation
To distinguish the role of XIAP in the proliferation of breast cancer cells, MTS assay was carried out at 0, 24, and 48 h subsequent of silencing (Fig. 2). Cell growth was significantly reduced in XIAP siRNA treated cells compared to the scrambled siRNA treated and non-treated cells (P < 0.05).

XIAP silencing-regulated proteins
According to the first set of statistical analysis, the differences in the proteins expression which are regulated by XIAP were identified at 48 h post-transfection due to the low expression level of XIAP protein at this time. Following 2D gel analysis, approximately 1000 well-resolved spots were detected in each gel (Fig. 3). Then, the nature of DEPs were assessed by the mass spectrometry. The Uniprot entry of the DEPs along with their main characteristics were presented in Table 2. It is apparent from this table that the expression of 30 proteins are altered in response to the XIAP silencing than si-NEG treated cells, of which 27 down-regulated and 3 up-regulated. The scores of theoretical mass and isoelectric point were compared in order to the accuracy of the identified DEPs. The result indicates that these scores are nearly the same, suggesting that they could be closely located on 2D-PAGE.

Furthermore, to verify the proteomics results, the level of four proteins was assessed by the quantitative real-time PCR. The expression level of these genes confirmed the 2D-PAGE results (Table 3). The transcript expression fold of ENO1, CH60, CRK and SAM50 genes were 4.63, 5.81, 0.25 and 0.4, respectively.

Protein interactions and network analysis
The association and interaction of XIAP with other DEPs was analyzed by STRING. Figure 4a illustrates a complex network of XIAP-regulated proteins. From this data, it can be seen that XIAP did not directly interact with the identified DEPs in MCF-7 cells exposed to the XIAP siRNA. According to the STRING results, we found that XIAP interacts with Heat shock proteins (HSPs), HSP90B1 and HSPB1, and ALB based on the textmining criteria with minimum confidence. To assess the function of regulated proteins by XIAP, reconstruct a network by STRING molecular action (Fig. 4b). The molecular mechanism and type of interaction of XIAP with the DEPs were not realized.

The application of CytoHubba was used to identify the key nodes in the mentioned network. Figure 4c depicts a network of regulated proteins by XIAP according to the degree, betweenness centrality, and co-expression methods. The finding of this analysis indicated that HSP90AA1 and HSPA9 are key nodes in this network based on the degree method. While in terms of betweenness centrality, HSPA8 and ENO1 are critical nodes. Additionally, ENO1 gene activated other top 10 genes, and HSPA8 along with HSPD1 were regulated by others (Fig. 4d).

Gene ontology enrichment analysis
The number of genes involved in each class of biological process and molecular function was shown in Fig. 5. The GO enrichment analysis demonstrated that proteins regulated by XIAP are mostly involved in cellular and metabolic processes along with response to stimulus. Accordingly, these results suggested a critical role of XIAP in the action of these pathways.

Further analysis by KEGG pathway bioinformatics database showed that the involvement of XIAP molecular targets in various biological pathways. HSPs had a critical role in inhibition of apoptosis in cancer
pathway and MAPK signaling pathway. Cancer signaling pathways (hsa05200) showed that HSP90B1 promotes cell proliferation and evades apoptosis by activating of androgen receptor (AR) and PSA. Also, activation of PSA causes cell proliferation survival in prostate cancer signaling pathway. In MAPK signaling pathway (hsa04010), HSPA1A interacts with Evil and suppresses apoptosis by the inhibition of JNK. These results suggested that XIAP may plays important roles in a diverse set of non-apoptotic signaling pathway in breast cancer and may have potential value in tumor gene therapy (Fig. 6).

**Fig. 1** Expression of XIAP in response to XIAP silencing in MCF-7 cells. **a** Fold-change expression of XIAP gene. The expression level of XIAP mRNA was reduced in siRNA treated cells compared to the si-NEG after 24, 48 and 72 h post-transfection. **b** illustrates the \( P < 0.001 \); *** represents \( P < 0.0001 \). **b** Protein expression level of XIAP in response to XIAP siRNA. Western blot shows that the highest down-regulation of protein occurred in 48 h post-transfection. **c** Densitometry of XIAP protein bands. The results of western blot were quantified by ImageJ software in order to measure the density of protein bands. The si-NEG was employed as a control group which exhibits the normal expression quantity of XIAP. The densitometry analysis revealed the low amount of XIAP protein at 48 h after transfection.
Discussion

The main obstacle of cancer therapy is the identification of specific factor of tumor cells. Inhibitor of apoptosis proteins especially XIAP are one of the main influencing agents in carcinogenesis. The XIAP transcript has been frequently expressed in different cancers [10]. Interestingly, its expression in both triple positive (MCF-7) and triple negative (MDA-MB-231) breast cancer cells were equal and higher than the non-tumorigenic mammary epithelial cells (MCF-10), have noted the impact of XIAP in proliferation of breast tumor cells. Nevertheless, very little was found on the XIAP functional mechanism in breast cancer. Consequently, the present study was aimed to identify the protein targets regulated by XIAP in the proliferation of cancer cells in MCF-7 cell line.

Our data showed that down-regulation of XIAP resulted in the reduction of cell proliferation and changed the expression pattern of 30 proteins in MCF-7 cells. The interesting point of proliferation assay was that the most remarkable reduction in cell proliferation occurred at 48 h post-transfection ($P < 0.0001$); at the same time period that the expression of XIAP reduced. These findings
Table 2 Differentially expressed proteins in response to siRNA against XIAP in MCF-7 cells

| Spot | Gene product | Score | Uniprot ID | Biological process | Molecular function | Theoretical MW (KD)/pI | On gel MW (KD)/pI | Location | Ratio | Location |
|------|--------------|-------|------------|-------------------|--------------------|------------------------|-------------------|----------|-------|----------|
| 1    | GRP78        | 286   | P11021     | Protein metabolism| Chaperone activity | 72,402/5.07           | 77,112/4.65       | 9q33     | 0.33  | 12q23    |
| 2    | ENPL         | 82    | P14625     | Protein metabolism| Heat shock protein activity | 92,696/4.76           | 80,516/4.55       | 12q13    | 0.27  | 2.3      |
| 3    | ATPB         | 390   | P06576     | Metabolism, Energy pathways | Transporter activity | 56,525/5.26           | 52,427/4.65       | 10p15    | 0.66  | 5q31     |
| 4    | GDIB         | 103   | P50395     | Transport          | Auxiliary transport protein activity | 51,087/6.11           | 46,950/6.1      | Xq28     | 0.49  | 0.51     |
| 5    | GRP75        | 274   | P38646     | Protein metabolism| Chaperone activity | 73,920/5.87           | 71,587/5.9        | 5p15     | 2.3   | 0.49     |
| 6    | G6PD         | 257   | P11413     | Metabolism, Energy pathways | Catalytic activity | 59,675/6.39           | 55,639/6.1       | 5q31     | 0.51  | 0.49     |
| 7    | ENO1         | 735   | P06733     | Metabolism, Energy pathways | Catalytic activity | 47,481/7.01           | 45,701/6.3        | 1p36     | 3.3   | 0.65     |
| 8    | ALBU−PRDX2   | 73    | P20768     | Transport          | Transporter activity | 71,317/5.92           | 66,546/5.4        | 4q13     | 0.51  | 0.39     |
| 9    | TCPE−FKBP4   | 122   | P48643     | Protein metabolism| Chaperone activity | 60,089/5.45           | 64,545/5.3        | 5p15     | 0.64  | 12p13    |
| 10   | H571A−H571B  | 234   | P07900     | Protein metabolism| Chaperone activity | 70,294/5.48           | 71,325/5.3        | 6p21     | 0.68  | 0.41     |
| 11   | HSP7C−HSP7C  | 526   | P11142     | Protein metabolism| Heat shock protein activity | 71,082/5.37           | 71,261/5.4        | 14q24.1  | 0.68  | 1p12     |
| 12   | HS90A−NPM    | 32    | P06748     | Protein metabolism| Chaperone activity | 85,006/4.94           | 91,559/4.7        | 14q32    | 0.1   | 0.65     |
| 13   | CRK−PRDX6    | 103   | P46108     | Cell communication, Signal transduction | Receptor signaling complex scaffold activity | 338,675.38        | 29,195/5.0       | 17p13    | 0.03  | 0.63     |
| 14   | PA2G4        | 70    | Q9UQ80     | Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism | Transcription regulator activity | 44,101/6.13          | 70,963/6.3        | 12q13    | 0.63  | 0.39     |
| 15   | SERA         | 140   | O43175     | Metabolism; Energy pathways | Catalytic activity | 57,356/6.29           | 77,142/5.4        | 1p12     | 2.72  | 0.65     |
| 16   | TBA1B        | 840   | P68363     | Cell growth and/or maintenance | Structural molecule activity | 50,804/4.94           | 58,606/4.6        | 12q13    | 0.65  | 0.65     |
| 17   | KPYM−SAM50   | 36    | O9Y512     | unknown           | unknown            | 52,342/6.44           | 17,144/5.4        | 22q13    | 0.07  | 0.63     |
| 18   | PRDX6−IF5A1  | 112   | P30041     | Metabolism, Energy pathways | Peroxidase activity | 25,133/6.00           | 27,314/5.9        | 1q25     | 0.06  | 0.63     |
| 19   | H571A−H571B  | 234   | P07900     | Protein metabolism| Chaperone activity | 32,726/6.44           | 38,294/4.3        | 5q31     | 0.65  | 0.65     |
| 20   | CH60−TPZ2    | 414   | P04792     | Protein metabolism| Transcription regulator activity | 22,826/5.98           | 20,312/5.7        | 7q11     | 0.41  | 0.41     |
| 21   | CH60−H571A−H571B | 623 | P10809     | Protein metabolism| Heat shock protein activity | 61,187/5.70           | 68,904/5.4        | 2q33     | 2.3   | 2.3      |
| 22   | TCP2−TBBS    | 93    | P40227     | Protein metabolism| Chaperone activity | 58,444/6.23           | 60,904/6.0        | 7q11     | 0.44  | 0.44     |
| 23   | IF5A1        | 90    | P63241     | Protein metabolism| Translation factor activity, nucleic acid binding | 17,049/5.08           | 164/4.8          | 17p13    | 0.6   | 0.6      |
| 24   | EF1G         | 148   | P26641     | Protein metabolism| Translation regulator activity | 50,429/6.25           | 53,625/5.9        | 11q12    | 0.5   | 0.5      |
| 25   | PDIA1        | 635   | P07237     | Protein metabolism| Isomerase activity | 57,480/4.76           | 60,784/4.5        | 17q25    | 0.83  | 0.83     |

*The product of CH60, ENO1, and GDIB genes were increasingly expressed (> twofold)*
further confirm the idea of XIAP involvement into the signaling pathways relevant to the oncogenesis or progression of the MCF-7 cells through the enrichment analysis of DEPs (Fig. 5).

By silencing of XIAP, ENO1 (+3.3) was the first highly expressed protein. From the oncology point of view, this protein acts in cell progression, apoptosis, and tumor cell invasion processes through repression of MYC gene [15] and activation of FAK in the PI3K/AKT pathway [16]. It introduced as an oncogene-associated protein in hepatocellular carcinoma [17]. Our research team also revealed the association of enhanced expression of ENO1 with PTTG1 [11]. Likewise, this protein participates in glycolysis and HIF1 signaling pathways to promote anaerobic metabolism (hsa04066). Interestingly, our network analysis displayed the impact of ENO1 as an activator of the top 10 genes.

The last two up-regulated proteins were GDIB (P50395) and CH60 (P10809) with 2.3 fold change expression ratio. The increased transcription of both genes were indicated in breast invasive carcinoma [10]. GDP dissociation inhibitor 2 was introduced as a suppressor of tumor metastasis and invasion [18]. It has been shown that low expression of GDIB is associated with increased metastasis risk and decrease survival in patients harboring bladder cancer. Also, other researcher demonstrated that XIAP silencing resulted in the decline of GDIB expression accompanied with reduced cell invasion in bladder cancer [19]. Although, our current findings do not support the earlier research. This inconsistency may be due to the different cancer types.

CH60 protein, a typical mitochondrial chaperone with tumor suppressor activity, is participated in the cancer cell progression. It has been localized in the ER during breast cancer cell apoptosis [20]. It was reported that HSP60 silencing considerably increased the migration and invasion phenotypes in the head and neck cancer cells [21]. They mentioned that deficiency of Hsp60 tumor suppression function contributed to the aggressive cancers. As a result, down-regulation of XIAP may cause the up-regulation of HSP60 which could be resulted in the activation of apoptosis and reduced the proliferation of cells (Fig. 6).

We found that the HSPs production (# 12) reduced by the treatment of XIAP siRNA except HSP60. Their functional mechanism was demonstrated in post-translational regulation of signaling molecules, protein folding, and inhibition of apoptosis under stressful situation [22, 23]. High expression of these molecules has been reported in various cancers, suggesting their contribution to the survival of tumor cells [10, 24]. They are crucial for the maintenance of cell integrity during both normal cell growth and pathophysiological condition [25, 26]. The involvement of HSPs in tumor development were indicated with distinct immunologic mechanisms promoting cell growth [27, 28]. These molecules have an important role in the apoptosis inhibition and promotion of cell proliferation in different signaling pathways including MAPK signaling and pathways in cancer (Fig. 6).

The observed finding in this study corroborated the results of a wide number of previous works that have examined the activity of HSPs in cancer related pathways [22]. For instance, HSP70 is the most central family of stress proteins that recently empirical evidence introduced XIAP as a client of Hsp70 in MDA-MB-231 breast cancer cells [29]. Our proteomics results showed that expression of HSP70 has reduced after silencing of XIAP gene. It has been exhibited that the resistance to apoptosis in some tumors is due to the binding between HSP70 and the apoptosis protease activating factor (Apaf-1) gene [30]. Also, these findings are in line with a prior study that revealed multiple HSP70-binding sites on XIAP [31]. It can then be assumed that the XIAP protein participates in apoptosis by affecting the expression of HSP70 through the MAPK-signaling pathway (Fig. 6).

Moreover, we found that the expression of HSP90 isoforms has reduced after XIAP silencing. HSP90 is a molecular chaperone that is up-regulated in various cancer types and required for the folding of numerous signaling proteins.

In this study, silencing of XIAP attenuated the expression of glucose-regulated protein, GRP78. It is an endoplasmic reticulum (ER) chaperone initially discovered as proteins inducible by glucose starvation [32]. Although GRP78 is predominantly found within the ER lumen, recent studies have shown that it can redistribute, under
ER stress condition, tumor cell surface and mitochondria [33, 34]. Li N, Zoubeidi et al. showed that under ER stress, GRP78 and Clusterin function cooperatively mediated the anti-apoptotic effects in the mitochondria pathway [35]. GRP94 is the resident HSP90 molecular chaperone that modulates protein folding, processing, and secretion. Our data showed that HSP90B1 have a critical role in cancer signaling pathway. In this pathway, HSP90B1 promotes the proliferation of cancer cells and their resistance to apoptosis by activating of PSA (Fig. 6).
It has also been reported that HSP90B1 helps cells to escape apoptosis and influence the function of various proto-oncogenes that are essential for breast cancer growth [26]. The role of this protein in prostate cancer cell proliferation was demonstrated by activating androgen receptor (AR). The interaction between AR and the promoter region of HSPA1B in this cell line was resulted in the regulation of HSP70 [36].

It is possible, therefore, that XIAP silencing could be a major factor, if not the only one, causing inhibition of cell progression and apoptosis induction by reduction of HSPs expression such as HSP90 and HSP90B1. However, this is an imperative issue for further research to explore on the molecular action of XIAP in apoptosis induction through HSPs members.
Conclusion
In conclusion, our results showed that XIAP protein may have diverse role in the biological signaling pathways by altering expression profile of other proteins especially, HSPs family. The present study provides additional evidence on the XIAP-mediated inhibition of apoptosis and enhancement of cell proliferation in breast cancer in vitro. These findings will almost certainly be much perused and scrutinized. However, in further research, it might be possible to determine the regulated proteins by XIAP in different breast cancer cell lines. Indeed, more investigation on this topic necessitates to be undertaken before the association between XIAP and breast cancer is more clearly understood. Notwithstanding these limitations, the study offers some insight into the type of interactions between XIAP and its regulated proteins.

Acknowledgements
We are grateful to the Golestan University of Medical Sciences and the AryaTinaGene Biopharmaceutical Company for their financial assistance. We express our appreciation and gratitude to the VProteomics Company for assistance with Mass spectrometry technique and for sharing their expertise with us during this research.

Authors’ contributions
MG initiated and supervised the project. He also helped in the final edition of paper and edited paper. MAG performed all libatory experiments and analyzed the data. He assisted in the paper writing. FTS analyzed the proteomics and bioinformatics data as well as wrote the paper. AV performed the 2D experiment, data analysis and co-wrote the paper. MG involved in cell culture establishment method. GDJ involved in Mass Spectrometry assay. All authors read and approved the final manuscript.

Funding
This work was supported by the Golestan University of Medical sciences (grant number 930514100) and the AryaTinaGene Biopharmaceutical Company.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This research is approved by ethics committee of Golestan University of Medical Science (#14791793061924).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflicts of interest.

Author details
1 Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Zip Code: 4934174515, Gorgan, Iran. 2 Department of Biotechnology, Gorgan University of Agricultural Sciences and Natural Resources, Gorgan, Iran. 3 VProteomics, K-37A, Ground Floor Green Park Main, New Delhi 110016, India. 4 AryaTinaGene Biopharmaceutical Company, Gorgan, Iran.

Received: 28 December 2019 Accepted: 26 May 2020 Published online: 11 June 2020

References
1. Hickman JA. Apoptosis and tumourigenesis. Curr Opin Genet Dev. 2002;12(1):67–72.
2. Uren AG, Coulson EJ, Vaux DL. Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. Trends Biochem Sci. 1998;23(5):159–62.
3. Takahashi R, Deveryaux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem. 1998;273(14):7787–90.
4. Li J, Feng Q, Kim J-M, Schneiderman D, Liston P, Li M, et al. Human Ovarian Cancer and Cisplatin Resistance: possible Role of Inhibitor of Apoptosis Proteins** This work was supported by grants from the Canadian Institutes of Health Research (MOP-15691), the University of Ottawa-Industry Grants Program, and the Ottawa Civic Hospital Foundation. Endocrinology. 2001;142(1):370–80.
5. Satoh K, Kanoke K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human prostatic duct cell tumors. Cancer. 2001;92(2):271–8.
6. Holcik M, Korneluk RG. OPINION: XIAP, the guardian angel. Nat Rev Mol Cell Biol. 2001;2(7):550.
7. Saleem M, Qadir MI, Perveen N, Ahmad B, Saleem U, Iqbal T, et al. Inhibitors of apoptotic proteins: new targets for anticancer therapy. Chem Biol Drug Des. 2013;82(3):243–51.
8. Ferreira C, Van Der Valk P, Span S, Jonker J, Postmus P, Kuypj F, et al. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol. 2001;12(6):799–805.
9. Sashaki H, Sheng Y, Kotsui F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000;60(20):5659–66.
10. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPAM: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–102.
11. Khazaie G, Shamsabadi FT, Yamchi A, Golalipour M, Jhingan GD, Shaahbazi M. Proteomics evaluation of MDA-MB-231 breast cancer cells in response to RNAi-induced silencing of H1PTG. Life Sci. 2019;239:116873.
12. Mayahi S, Golalipour M, Yamchi A, Jhingan GD, Shaahbazi M. New insights into the roles of the FOXO3 and P27Kip1 genes in signaling pathways. Upsala J Med Sci. 2019;124(3):149–57.
13. Sadeghi H, Golalipour M, Yamchi A, Farzamendfar T, Shaahbazi M. CDC25A pathway toward tumorgenesis: molecular targets of CDC25A in cell cycle regulation. J Cell Biochem. 2018;120(3):2919–28.
14. Bouyssie D, de Peredo AG, Mouton E, Albogt R, Roussel L, Ortega N, et al. Mascot File Parsing and Quantification (MFPaQ), a New Software to Parse, Validate, and Quantify Proteomics Data Generated by ICAT and SILAC Mass Spectrometric Analyses. Application To the Proteomics Study of Membrane Proteins from Primary Human Endothelial Cells. Mol Cell Proteomics. 2007;6(9):1621–37.
15. Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A. ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett. 2000;473(1):47–52.
16. Fu GF, Liu Y, Fan Y, Hua SN, Qu HY, Dong SW, et al. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol. 2018;12(3):2919–28.
17. Zhu W, Li H, Yu Y, Chen J, Chen X, Ren F, et al. Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients. Cancer Manag Res. 2018;10:5735.
18. Liu L, Wang Y, Chen W. XIAP promotes cell proliferation and invasion in human glioma cells. Biochem Biophys Res Commun. 2002;295(2):297–300.
19. Yu Y, Jin H, Xu J, Gu J, Li X, Xie Q, et al. XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIβ RNA stability. Int J Cancer. 2018;142(10):2040–55.
20. Arya RK, Singh A, Yadav NK, Cheruvu SH, Hossain Z, Meena S, et al. Anti-breast tumor activity of Eclipta extract in vitro and in vivo: novel evidence of endoplasmic reticulum specific localization of Hsp60 during apoptosis. Sci Rep. 2015;5:18457.
21. Chiu C-C, Lin C-Y, Lee L-Y, Chen Y-J, Lu Y-C, Wang H-M, et al. Molecular chaperones as a common set of proteins that regulate the invasion phenotype of head and neck cancer. Clin Cancer Res. 2011;17(14):4629–41.

22. Kennedy D, Jäger R, Mosser DD, Samali A. Regulation of apoptosis by heat shock proteins. IUBMB Life. 2014;66(5):327–38.

23. Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Ulrich Hartl F. Molecular chaperones in protein folding and proteostasis. Annu Rev Biochem. 2013;82:323–55.

24. Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausel S, Boni L, et al. The role of heat shock proteins in cancer. Cancer Lett. 2015;360(2):114–8.

25. Nollen EA, Morimoto RI. Chaperoning signaling pathways: molecular chaperones as stress-sensing heat shock proteins. J Cell Sci. 2002;115(14):2809–16.

26. Takayama S, Reed JC, Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene. 2003;22(56):9041.

27. Luk JM, Lam CT, Siu AF, Lam BY, Ng IO, Hu MY, et al. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics. 2006;6(3):1049–57.

28. Wang H, Liu Y, Yang S, Duan C, Wang Y, Zhao J, et al. Expression of HSP70 Grp94 and IgG in human lung carcinoma. Chin J Cell Mol Immunol. 2008;24(5):447–9.

29. Cesa LC, Shao H, Srinivasan SR, Tse E, Jain C, Zuiderveld ER, et al. X-Linked Inhibitor of Apoptosis Protein (XIAP) is a Client of Heat Shock Protein 70 (Hsp70) and a Biomarker of its Inhibition. J Biol Chem. 2018;293(7):2370–80.

30. Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol. 2000;2(8):476.

31. Cesa LC, Shao H, Srinivasan SR, Tse E, Jain C, Zuiderveld ER, et al. X-Linked Inhibitor of Apoptosis Protein (XIAP) is a Client of Heat Shock Protein 70 (Hsp70) and a Biomarker of its Inhibition. J Biol Chem. 2017;293(7):2370–80.

32. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci. 2001;26(8):504–10.

33. Davidson DJ, Haskell C, Majest S, Kherzai A, Egan DA, Walter KA, et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res. 2005;65(11):4663–72.

34. Ni M, Zhang Y, Lee AS. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J. 2011;434(2):181–8.

35. Li N, Zoubiedad A, Berald E, Gleave M. GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer. Oncogene. 2013;32(15):1933.

36. Lu S, Tan Z, Wortman M, Dong Z. Regulation of heat shock protein 70-1 expression by androgen receptor and its signaling in human prostate cancer cells. Int J Oncol. 2010;36(2):459–67.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.